Dihydroxyphosphinothioyl octadec-9-enoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机硫代磷酸及其衍生物
• 英文名称: Dihydroxyphosphinothioyl octadec-9-enoate
• 英文别名: dihydroxyphosphinothioyl octadec-9-enoate
• 化学式: C₁₈H₃₅O₄PS
• 分子量: 378.5
• InChiKey: GPSIVZCZXOOOHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  24
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  98.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] LPA RECEPTOR AGONISTS AND ANTAGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS DE LPA ET ANTAGONISTES
  申请人：RXBIO INC

  公开号：WO2010051053A1

  公开（公告）日：2010-05-06

  Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including treating cancer, producing radioprotection and/or radiomitigation, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermato logical condition.

  揭示了按照式(I)的化合物，以及包括这些化合物的药物组合物。还揭示了使用这些化合物的方法，这些方法具有作为LPA受体激动剂或拮抗剂的活性；这些方法包括治疗癌症、产生放射保护和/或减轻放射损伤、增强细胞增殖、治疗伤口、治疗凋亡或在细胞、组织或器官中保护或恢复功能、培养细胞、保护器官或组织功能，以及治疗皮肤病理条件。
• Traction drive fluid
  申请人：Nippon Mitsubishi Oil Corporation

  公开号：US20010010293A1

  公开（公告）日：2001-08-02

  A traction drive fluid comprising a naphthenic compound represented by the formula 1 wherein R 1 is an alkyl group, which may have a naphthene ring, having 1 to 8 carbon atoms, R 2 through R 4 are each independently hydrogen or an alkyl group, which may have a naphthene ring, having 1 to 8 carbon atoms, and A is a naphthenic hydrocarbon group, a saturated polycyclic hydrocarbon group, a naphthenic ester group, and a naphthenic carbonate group.

  一种牵引传动液，包括一种由以下式子1表示的萘烷化合物： 式子1 其中，R1是一个碳数为1到8的烷基团，可能有一个萘环；R2到R4各自独立地是氢原子或碳数为1到8的烷基团，可能有一个萘环；A是一个萘烷烃基团、一个饱和多环烃基团、一个萘烷酯基团或一个萘烷碳酸酯基团。
• LPA receptor agonists and antagonists and methods of use
  申请人：Miller D. Duane

  公开号：US20060009507A1

  公开（公告）日：2006-01-12

  The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

  本发明涉及公式（I）所示的化合物，以及包括这些化合物的制药组合物。还公开了使用这些化合物的方法，这些化合物具有作为LPA受体的激动剂或拮抗剂的活性；这些方法包括抑制LPA受体上的LPA活性，调节LPA受体活性，治疗癌症，增强细胞增殖，治疗伤口，治疗凋亡或在细胞、组织或器官中保持或恢复功能，培养细胞，保护器官或组织功能，以及治疗皮肤病症。
• LPA Receptor Agonists and Antagonists and Methods of Use
  申请人：Miller D. Duane

  公开号：US20080090783A1

  公开（公告）日：2008-04-17

  Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

  本发明涉及化合物(I)及包含该化合物的药物组合物。还揭示了使用这些化合物的方法，这些方法具有作为LPA受体激动剂或拮抗剂的活性；这些方法包括抑制LPA受体上的LPA活性，调节LPA受体活性，治疗癌症，增强细胞增殖，治疗创伤，治疗凋亡或保护或恢复细胞、组织或器官的功能，培养细胞，保护器官或组织功能，以及治疗皮肤病症。
• LPA Receptor Agonists and Antagonists
  申请人：Gududuru Veeresh

  公开号：US20120010424A1

  公开（公告）日：2012-01-12

  Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including treating cancer, producing radioprotection and/or radiomitigation, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermato logical condition.

  本发明涉及公式（I）所示的化合物，以及包括这些化合物的制药组合物。本发明还涉及使用这些化合物的方法，这些化合物具有作为LPA受体的激动剂或拮抗剂的活性；这些方法包括治疗癌症、产生放射保护和/或减轻放射损伤、增强细胞增殖、治疗伤口、治疗凋亡或保护或恢复细胞、组织或器官的功能、培养细胞、保护器官或组织功能，以及治疗皮肤病症。